open access

Vol 10, No 2 (2005)
Original Paper
Published online: 2005-01-01
Submitted: 2004-04-02
Get Citation

Correlation between pre-therapeutic TPS and VEGF concentrations, in the serum of patients with cancer of the uterine cervix, and early effects of therapy

Małgorzata Rusiecka, Paweł Sedlaczek, Antonina Harłozińska-Szmyrka, Jan Kornafel
DOI: 10.1016/S1507-1367(05)71113-5
·
Rep Pract Oncol Radiother 2005;10(2):17-23.

open access

Vol 10, No 2 (2005)
Original Paper
Published online: 2005-01-01
Submitted: 2004-04-02

Abstract

Aim

To assess the relationship between pre-therapeutic serum TPS and VEGF levels and the results of treatment as measured immediately after completion of therapy.

Materials/Methods

The study included 146 women treated for cancer of the uterine cervix. Of these, 37 women were in stage I, 43 in stage II, 59 in stage III and 7 in stage IV of disease progression according to the FIGO classification. The ages of the patients ranged from 31 to 80 years. The dominant cancer observed was squamous cell carcinoma which accounted for more than 97% of cases. Samples were taken before commencement of treatment. Patients were treated by a combination of methods including radiochemotherapy, radical radiotherapy and palliative radiotherapy. The effects of therapy were graded after completion of irradiation according to generally accepted criteria. For tested criteria, ROC curves were drawn, determining cut-off points of 58 U/l for TPS and 500 pg/l for VEGF. For statistical calculations the U Mann-Whitney test was used.

Results

The level of VEGF expression varied between groups of patients in certain stages of disease progression (stages 1 & 2 and stages 2 & 3). Statistically significant differences were found between group PR in stage 2 and a control group of healthy women. Entry levels of TPS rose with tumor advancement (in stages 2, 3 & 4) and were higher than in a group of healthy women. Detected differences were statistically significant.

Conclusions

Only pre-therapeutic TPS levels show definite differences between degrees of clinical advancement and also with early therapeutic effects. Comparatively higher levels of serum TPS were found in patients with the worst prognosis prior to treatment (group P) than in the control group. This difference is statistically significant. Pre-therapeutic VEGF levels showed statistically significant differences between early (I, II) and advanced (III) clinical stages of the tumor as well as some effects of therapy assessed immediately after completion of treatment (PR vs S).

Abstract

Aim

To assess the relationship between pre-therapeutic serum TPS and VEGF levels and the results of treatment as measured immediately after completion of therapy.

Materials/Methods

The study included 146 women treated for cancer of the uterine cervix. Of these, 37 women were in stage I, 43 in stage II, 59 in stage III and 7 in stage IV of disease progression according to the FIGO classification. The ages of the patients ranged from 31 to 80 years. The dominant cancer observed was squamous cell carcinoma which accounted for more than 97% of cases. Samples were taken before commencement of treatment. Patients were treated by a combination of methods including radiochemotherapy, radical radiotherapy and palliative radiotherapy. The effects of therapy were graded after completion of irradiation according to generally accepted criteria. For tested criteria, ROC curves were drawn, determining cut-off points of 58 U/l for TPS and 500 pg/l for VEGF. For statistical calculations the U Mann-Whitney test was used.

Results

The level of VEGF expression varied between groups of patients in certain stages of disease progression (stages 1 & 2 and stages 2 & 3). Statistically significant differences were found between group PR in stage 2 and a control group of healthy women. Entry levels of TPS rose with tumor advancement (in stages 2, 3 & 4) and were higher than in a group of healthy women. Detected differences were statistically significant.

Conclusions

Only pre-therapeutic TPS levels show definite differences between degrees of clinical advancement and also with early therapeutic effects. Comparatively higher levels of serum TPS were found in patients with the worst prognosis prior to treatment (group P) than in the control group. This difference is statistically significant. Pre-therapeutic VEGF levels showed statistically significant differences between early (I, II) and advanced (III) clinical stages of the tumor as well as some effects of therapy assessed immediately after completion of treatment (PR vs S).

Get Citation

Keywords

VEGF; TPS; cancer of the uterine cervix

About this article
Title

Correlation between pre-therapeutic TPS and VEGF concentrations, in the serum of patients with cancer of the uterine cervix, and early effects of therapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 10, No 2 (2005)

Pages

17-23

Published online

2005-01-01

DOI

10.1016/S1507-1367(05)71113-5

Bibliographic record

Rep Pract Oncol Radiother 2005;10(2):17-23.

Keywords

VEGF
TPS
cancer of the uterine cervix

Authors

Małgorzata Rusiecka
Paweł Sedlaczek
Antonina Harłozińska-Szmyrka
Jan Kornafel

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl